Search results
Results from the WOW.Com Content Network
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Lanreotide (as lanreotide acetate) is manufactured by Ipsen.
Another peptide known to self-assemble is the octapeptide Lanreotide. This compound is a synthetic analogue of the peptide hormone somatostatin and it is used to treat acromegaly [6] (a condition where the body produced too much growth hormone). In water, Lanreotide self-assembles into monodisperse liquid crystalline nanotubes. The nanotubes ...
Sermorelin acetate (INN Tooltip International Nonproprietary Name; brand names Geref, Gerel), also known as GHRH (1-29), is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency.
In other cases, imaging can be performed by labelling a suitable radionuclide to the same peptide as used for therapy. [22] Radionuclides that can be used for imaging include gallium-68, technetium-99m and fluorine-18. [21] Currently used peptides can result in high kidney doses, as the radiopharmaceutical is retained for relatively long ...
Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. [1] [2] [3] It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. [4]
Pasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012 [2] [9] and by the U.S. Food and Drug Administration (FDA) in December 2012. [ 1 ] [ 10 ] Pasireotide LAR (the long-acting-release formulation) was approved by the FDA for treatment of acromegaly in December 2014, [ 11 ] and had been approved for ...
For premium support please call: 800-290-4726 more ways to reach us
LSD, like many other drugs of recreational use, has been shown to activate DARPP-32-related pathways. [122] The drug enhances dopamine D 2 receptor protomer recognition and signaling of D 2 –5-HT 2A receptor complexes, [ 123 ] which may contribute to its psychotropic effects. [ 123 ]